P4, N=20, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o

P2, N=30, Not yet recruiting, The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University

P2, N=236, Recruiting, The Sixth Affiliated Hospital of Sun Yat-sen University; The Sixth Affiliated Hospital of Sun Yat-sen University | Not yet recruiting --> Recruiting

We identified a novel four mucin-characterized subtypes, which advance precision medicine by refining chemotherapy regimen selection. Our study provides valuable insights for tailoring therapeutic strategies.

Nivolumab plus chemotherapy demonstrated modest efficacy and acceptable toxicity in patients with AGC and HAB.

The patient completed 6 months of adjuvant mFOLFOX6, as recommended in the MAC-colon cancer guidelines...At 4 months after the last systemic therapy, the patient's biomarkers were rising, matching radiological local, ovarian, and pleural recurrences, which were histologically confirmed. Since there are no established guidelines for MAC-RP, our team is the first to apply cutting-edge cancer technologies to inform future clinical decisions and molecular tumor board discussions and to compare the genomic distance of MAC-RP with that of other bladder or colorectal origin sites.

CAF exposure enhanced SIAH2 expression, CSC spheroid growth, and resistance to fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy, whereas SIAH2 depletion effectively abrogated these effects. Collectively, these findings identify the SIAH2/WNK1 axis as a central metabolic regulator linking glycolysis, CSC maintenance, and microenvironment-driven therapy resistance in CRC, highlighting its potential as a therapeutic target.

Although MAPK alterations are pervasive in CRC, their distribution varies meaningfully by ancestry, age, and treatment exposure. These findings highlight NF1, MAPK3, RPS6KA4, and PDGFRB as potential biomarkers in EOCRC and H/L patients, supporting the need for ancestry-aware precision oncology approaches.

RTK-RAS pathway alterations demonstrate strong age-, ancestry-, and treatment-specific prognostic effects and may serve as precision biomarkers of differential chemotherapy response. AI-enabled analytics substantially accelerated integrative biomarker discovery, supporting their utility for advancing precision oncology in EOCRC.

P=N/A, N=30, Active, not recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Jul 2025

Based on this finding, the patient was treated with trastuzumab plus FOLFOX followed by trastuzumab deruxtecan (T-DXd), achieving a durable response...It also illustrates the potential role of CGP in identifying overlooked therapeutic targets and guiding subsequent treatment decisions in gastric cancer. CGP may serve as a useful adjunct to conventional diagnostics, particularly when initial testing is inconclusive or based on metastatic tissue.

Changes in the percentage of CD4+ cells and CD16/56+ cells under depression were moderated by 5-HTTLPR alleles among CRC patients undergoing FOLFOX chemotherapy, suggesting a gene-environment interaction. Further research on the role of 5-HTTLPR in the immune system under depression among CRC patients is warranted.